Features

As we move past the mid-way mark in 2022, how has the industry fared with new drug approvals? Is the industry keeping pace with prior years’ innovation levels? What do the  numbers show, including the mix between small molecules and biologics?

The European Union agreed this week to reduce natural gas demand by 15%, starting August 1 and lasting through next March, to prepare for possible disruptions of gas supplies from Russia. The EU chemical and pharma industries weigh in.

GlaxoSmithKline has completed the spin-off of its consumer healthcare business to form a separate stand-alone $11-billion company, Haleon. The move is part of a larger strategic plan by GSK’s CEO Emma Walmsley to drive growth in its core bio/pharmaceuticals business. What is next for the New GSK?

How are the skillsets for sourcing, procurement, and supply management professionals evolving to meet future talent needs, including digital capabilities? What will be needed for effective supplier relationship management in the future both from pharma companies and suppliers?

What have been some key recent investments in manufacturing by the large bio/pharmaceutical companies? What areas, small-molecule APIs, biologics, or drug products, have been attracting the investment dollars? DCAT Value Chain Insights rounds up key projects.

A recent US government report evaluated the FDA’s process for for-cause inspections of foreign drug-manufacturing facilities. Although the FDA has made changes to improve the process, Congress and others have raised concerns. What did the review show?

Growth in the oncology drug market continues to spur demand for high-potency API manufacturing. Which CDMOs/CMOs are expanding? DCAT Value Chain Insights rounds up the latest investments.

Novartis is implementing a $1-billion restructuring plan and is deciding on its options for its generics and biosimilars business, Sandoz. What moves may be next for the company?

How has the FDA performed in mitigating drug shortages and in its inspection activity since the COVID-19 pandemic? Has it been able to keep drug shortages down and keep pace with its inspection activity on levels on par pre-pandemic? Two recent reports tell the story.

Having resilient supply chains is always of great importance, but even more so as customers and suppliers have had to adjust to new challenges in the wake of the pandemic. What are some innovative practices that companies are applying to their supply chain?